PMID- 30391538
OWN - NLM
STAT- MEDLINE
DCOM- 20200724
LR  - 20220408
IS  - 1522-9653 (Electronic)
IS  - 1063-4584 (Linking)
VI  - 27
IP  - 5
DP  - 2019 May
TI  - Cartilage oligomeric matrix protein, C-terminal cross-linking telopeptide of type 
      II collagen, and matrix metalloproteinase-3 as biomarkers for knee and hip 
      osteoarthritis (OA) diagnosis: a systematic review and meta-analysis.
PG  - 726-736
LID - S1063-4584(18)31513-9 [pii]
LID - 10.1016/j.joca.2018.10.009 [doi]
AB  - OBJECTIVE: This study was design to examine the diagnostic performance of 
      cartilage oligomeric matrix protein (COMP), C-terminal cross-linking telopeptide 
      of type II collagen (CTX-II), and matrix metalloproteinase-3 (MMP-3) as biomarker 
      for knee and hip OA. METHODS: Systematic search on multiple databases was 
      completed in January 2018 using certain keywords. COMP, CTX-II, MMP-3 levels in 
      knee and hip OA patients and healthy individuals were collected and calculated. 
      Differences between subgroups were expressed as standardized mean differences 
      (SMD). Subgroup analyses were performed to compare COMP, CTX-II, and MMP-3 
      performance between measuring sources, genders, large and small sample size and 
      diagnostic criteria for OA patients. RESULTS: A moderate performance of COMP in 
      distinguishing between knee (SMD: 0.68; 95% confidence intervals (CI): 0.43-0.93; 
      P < 0.0001) or hip (SMD: 0.25; 95% CI, 0.10, 0.40; P = 0.0008) OA patients and 
      controls were found. CTX-II showed a moderated standardised mean differences 
      (SMD) of 0.48 (95% CI, 0.32, 0.64; P < 0.0001) in the detection of knee OA and a 
      large SMD of 0.76 (95% CI, 0.09, 1.42; P = 0.03) in diagnosing hip OA. A small 
      SMD of 0.32 (95% CI, -0.03, 0.67; P = 0.07) was found for MMP-3 performance and 
      the results did not reach statistic significance. Progression study revealed 
      potential effectiveness of serum COMP in predicting OA progression. Subgroup 
      analysis showed that serum COMP and urinary CTX-II performed better in male than 
      female. Study size and diagnostic criteria did not significantly influence the 
      pooled SMD, but they might be the sources of heterogeneity among studies. 
      CONCLUSION: The overall results indicates that serum COMP and urinary CTX-II can 
      distinguish between knee or hip OA patients and control subjects. Serum COMP is 
      effective in predicting OA progression.Further researches with rigorous study 
      design and a larger sample size are required to validate our findings.
CI  - Copyright (c) 2018. Published by Elsevier Ltd.
FAU - Hao, H Q
AU  - Hao HQ
AD  - School of Basic Medicine, Shanxi University of Chinese Medicine, Taiyuan 030001, 
      Shanxi, China.
FAU - Zhang, J F
AU  - Zhang JF
AD  - School of Management, Shanxi Medical University, Taiyuan 030001, Shanxi, China; 
      Shanxi Medical Health Media Group Co.,Ltd, Taiyuan 030001, Shanxi, China. 
      Electronic address: sxzhangjf163@163.com.
FAU - He, Q Q
AU  - He QQ
AD  - School of Management, Shanxi Medical University, Taiyuan 030001, Shanxi, China.
FAU - Wang, Z
AU  - Wang Z
AD  - School of Basic Medicine, Shanxi University of Chinese Medicine, Taiyuan 030001, 
      Shanxi, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20181102
PL  - England
TA  - Osteoarthritis Cartilage
JT  - Osteoarthritis and cartilage
JID - 9305697
RN  - 0 (Biomarkers)
RN  - 0 (C-terminal cross-linking telopeptide of type II collagen, human)
RN  - 0 (Cartilage Oligomeric Matrix Protein)
RN  - 0 (Collagen Type II)
RN  - 0 (Peptide Fragments)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Biomarkers/*analysis
MH  - Cartilage Oligomeric Matrix Protein/analysis
MH  - Collagen Type II/analysis
MH  - Humans
MH  - Matrix Metalloproteinase 3/analysis
MH  - Osteoarthritis, Hip/*diagnosis
MH  - Osteoarthritis, Knee/*diagnosis
MH  - Peptide Fragments/analysis
MH  - Prognosis
OTO - NOTNLM
OT  - Biomarker
OT  - COMP
OT  - CTX-II
OT  - MMP-3
OT  - Osteoarthritis
EDAT- 2018/11/06 06:00
MHDA- 2020/07/25 06:00
CRDT- 2018/11/05 06:00
PHST- 2018/07/11 00:00 [received]
PHST- 2018/09/25 00:00 [revised]
PHST- 2018/10/08 00:00 [accepted]
PHST- 2018/11/06 06:00 [pubmed]
PHST- 2020/07/25 06:00 [medline]
PHST- 2018/11/05 06:00 [entrez]
AID - S1063-4584(18)31513-9 [pii]
AID - 10.1016/j.joca.2018.10.009 [doi]
PST - ppublish
SO  - Osteoarthritis Cartilage. 2019 May;27(5):726-736. doi: 
      10.1016/j.joca.2018.10.009. Epub 2018 Nov 2.